Drug class profile · refreshed daily from federal data

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

7 molecules in this class, $164.9M combined CY2024 Part D spend across 130K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $164.9Mcombined across class
Total Rx claims: 130K20K unique beneficiaries
Generic mfrs (active): 22across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Doravirine

Brand: PIFELTRO · 64K Part D claims (CY24) · 9K beneficiaries · First FDA approval: 2018-07-20

Brand-only (no generics) 0 plans require PA

Low NADAC$60.76

→

Avg plan cost$60.76

Part D spend $121.3M 1× spread, current vs floor

Class share

74%

of class CY24 spend

View profile →

Etravirine

Brand: Intelence · 33K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2008-01-18

3 generic mfrs 0 plans require PA

Low NADAC$7.77

→

Avg plan cost$11.22

Part D spend $35.4M 1× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Efavirenz

16K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2017-12-15

5 generic mfrs 0 plans require PA

Low NADAC$1.41

→

Avg plan cost$1.43

Part D spend $5.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nevirapine

17K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2012-05-22

7 generic mfrs 0 plans require PA

Low NADAC$0.153

→

Avg plan cost$0.710

Part D spend $2.4M 5× spread, current vs floor

Class share

of class CY24 spend

View profile →

Doravirine, Lamivudine, and Tenofovir Disoproxil

Brand: DELSTRIGO · — Part D claims (CY24) · First FDA approval: 2018-07-20

Brand-only (no generics) 0 plans require PA

Low NADAC$92.72

→

Avg plan cost$92.72

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Efavirenz, Emtricitabine and Tenofovir Disoproxil

— Part D claims (CY24) · First FDA approval: 2020-10-01

6 generic mfrs 0 plans require PA

Low NADAC$1.17

→

Avg plan cost$1.17

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Efavirenz, Lamivudine and Tenofovir Disoproxil

Brand: SYMFI · — Part D claims (CY24) · First FDA approval: 2018-04-25

1 generic mfrs 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.